[1] SAEEDI P, PETERSOHN I, SALPEA P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition[J]. Diabetes Res Clin Pract, 2019, 157: 107843. doi: 10.1016/j.diabres.2019.107843
[2] PSILOPANAGIOTI A, NIKOU S, PAPADAKI H. Nucleobindin-2/nesfatin-1 in the human hypothalamus is reduced in obese subjects and colocalizes with oxytocin, vasopressin, melanin-concentrating hormone, and cocaine- and amphetamine-regulated transcript[J]. Neuroendocrinology, 2019, 108(3): 190. doi: 10.1159/000496731
[3] DORE R, LEVATA L, LEHNERT H, et al. Nesfatin-1: functions and physiology of a novel regulatory peptide[J]. J Endocrinol, 2017, 232(1): R45. doi: 10.1530/JOE-16-0361
[4] NAKATA M, MANAKA K, YAMAMOTO S, et al. Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca2+ influx through L-type channels in mouse islet β-cells[J]. Endocr J, 2011, 58(4): 305. doi: 10.1507/endocrj.K11E-056
[5] YANG Y, ZHANG B, NAKATA M, et al. Islet β-cell-produced NUCB2/nesfatin-1 maintains insulin secretion and glycemia along with suppressing UCP-2 in β-cells[J]. J Physiol Sci, 2019, 69(5): 733. doi: 10.1007/s12576-019-00689-2
[6] AYADA C, TORU V, KORKUT Y. Nesfatin-1 and its effects on different systems[J]. Hippokratia, 2015, 19(1): 4.
[7] NAKATA M, YADA T. Role of NUCB2/nesfatin-1 in glucose control: diverse functions in islets, adipocytes and brain[J]. Curr Pharm Des, 2013, 19(39): 6960. doi: 10.2174/138161281939131127130112
[8] WU T, QIAO S, SHI C, et al. The metabolomics window into diabetic complications[J]. J Diabetes Investig, 2018, 9(2): 244. doi: 10.1111/jdi.12723
[9] IGELL I, SAUNDERS KH, FINS JJ. Why weight? An analytic review of obesity management, diabetes prevention, and cardiovascular risk reduction[J]. Curr Atheroscler Rep, 2018, 20(8): 39. doi: 10.1007/s11883-018-0740-z
[10] OH-I S, SHIMIZU H, SATOH T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus[J]. Nature, 2006, 443(7112): 709. doi: 10.1038/nature05162
[11] TACHÉ Y, STENGEL A. New developments on NUCB2/nesfatin-1[J]. Curr Pharm Des, 2013, 19(39): 6919. doi: 10.2174/138161281939131127122941
[12] SCHALLA MA, STENGEL A. Current understanding of the role of Nesfatin-1[J]. J Endocr Soc, 2018, 2(10): 1188. doi: 10.1210/js.2018-00246
[13] YANG M, ZHANG Z, WANG C, et al. Nesfatin-1 action in the brain increases insulin sensitivity through Akt/AMPK/TORC2 pathway in diet-induced insulin resistance[J]. Diabetes, 2012, 61(8): 1959. doi: 10.2337/db11-1755
[14] LI Z, GAO L, TANG H, et al. Peripheral effects of nesfatin-1 on glucose homeostasis[J]. PLoS One, 2013, 8(8): e71513. doi: 10.1371/journal.pone.0071513
[15] LIU F, YANG Q, GAO N, et al. Decreased plasma nesfatin-1 level is related to the thyroid dysfunction in patients with type 2 diabetes mellitus[J]. J Diabetes Res, 2014, 2014: 128014.
[16] ZHANG Z, LI L, YANG M, et al. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus[J]. Exp Clin Endocrinol Diabetes, 2012, 120(2): 91. doi: 10.1055/s-0031-1286339
[17] RIVA M, NITERT M D, VOSS U, et al. Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects[J]. Cell Tissue Res, 2011, 346: 393. doi: 10.1007/s00441-011-1268-5
[18] CHEN K, ZHUO T, WANG J, et al. Saxagliptin upregulates Nesfatin-1 secretion and ameliorates insulin resistance and metabolic profiles in type 2 diabetes mellitus[J]. Metab Syndr Relat Disord, 2018, 16(7): 336. doi: 10.1089/met.2018.0010